- Home
- NXTC vs BIAF Comparison
NXTC vs BIAF Comparison
Compare NXTC & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- BIAF
- Stock Information
- Founded
- NXTC 2015
- BIAF 2014
- Country
- NXTC United States
- BIAF United States
- Employees
- NXTC N/A
- BIAF N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NXTC Health Care
- BIAF Health Care
- Exchange
- NXTC Nasdaq
- BIAF Nasdaq
- Market Cap
- NXTC 13.9M
- BIAF 12.2M
- IPO Year
- NXTC 2019
- BIAF 2022
- Fundamental
- Price
- NXTC $6.17
- BIAF $0.33
- Analyst Decision
- NXTC Strong Buy
- BIAF Hold
- Analyst Count
- NXTC 3
- BIAF 1
- Target Price
- NXTC $33.00
- BIAF N/A
- AVG Volume (30 Days)
- NXTC 299.6K
- BIAF 2.7M
- Earning Date
- NXTC 08-04-2025
- BIAF 08-13-2025
- Dividend Yield
- NXTC N/A
- BIAF N/A
- EPS Growth
- NXTC N/A
- BIAF N/A
- EPS
- NXTC N/A
- BIAF N/A
- Revenue
- NXTC N/A
- BIAF $8,809,228.00
- Revenue This Year
- NXTC N/A
- BIAF N/A
- Revenue Next Year
- NXTC N/A
- BIAF $20.00
- P/E Ratio
- NXTC N/A
- BIAF N/A
- Revenue Growth
- NXTC N/A
- BIAF 78.40
- 52 Week Low
- NXTC $2.69
- BIAF $0.16
- 52 Week High
- NXTC $20.76
- BIAF $2.81
- Technical
- Relative Strength Index (RSI)
- NXTC 62.21
- BIAF 53.51
- Support Level
- NXTC $4.75
- BIAF $0.27
- Resistance Level
- NXTC $5.23
- BIAF $0.38
- Average True Range (ATR)
- NXTC 0.56
- BIAF 0.04
- MACD
- NXTC 0.10
- BIAF 0.00
- Stochastic Oscillator
- NXTC 86.74
- BIAF 60.95
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.